Variable | N = 718 | P | ||
---|---|---|---|---|
PO-HPD (101) | ER (418) | LR (199) | Â | |
Female(%) | 30 (29.7%) | 162 (38.8%) | 74 (37.2%) | 0.239 |
Age (y, mean ± SD) | 60.9(±9.27) | 63.2(±8.797) | 61.7(±8.21) | 0.011 |
BMI (kg/m [2], mean ± SD) | 22.8(±2.76) | 22.6(±3.30) | 22.8(±2.81) | 0.413 |
WBC(a10^9/L, mean ± SD) | 6.3(±2.42) | 5.9(±2.07) | 6.2(±1.88) | 0.063 |
Neutrophil(a10^9/L, mean ± SD) | 7.4(±14.79) | 5.4(±10.00) | 7.7(±14.34) | 0.130 |
Lymphocyte(a10^9/L, mean ± SD) | 1.6(±1.03) | 1.4(±0.55) | 1.5(±0.49) | 0.143 |
Monocyte(a10^9/L, mean ± SD) | 0.4(±0.18) | 0.4(±0.42) | 0.5(±0.20) | 0.001 |
RBC(a10^12/L, mean ± SD) | 4.3(±0.54) | 4.1(±0.55) | 4.2(±0.59) | 0.001 |
Albumin(g/L, mean ± SD) | 39.6(±4.24) | 39.1(±5.74) | 38.2(±4.85) | 0.085 |
LMR | 5.1(±9.10) | 4.2(±5.78) | 3.63(±1.51) | 0.774 |
PLR | 161.3(±111.80) | 158.3(±84.96) | 147.5(±67.84) | 0.549 |
NLR | 6.7(±16.25) | 4.5(±9.12) | 5.5(±10.72) | 0.831 |
SIRI | 2.5(±5.40) | 2.0(±4.47) | 2.6(±4.99) | 0.118 |
CA199 (U/mL, median with IQR) | 356.0 (96.2–1319.2) | 170.3 (46.6–630.3) | 102.4 (34.0–288.0) | < 0.0001 |
CA125(U/mL, median with IQR) | 22.6 (12.4–35.0) | 17.0 (11.4–30.0) | 14.7 (9.4–23.7) | < 0.0001 |
CEA (ng/mL, median with IQR) | 4.0 (2.3–6.8) | 3.5 (2.2–6.2) | 3.2 (1.8–6.6) | 0.250 |
Borderline resectable | 32 (31.7%) | 114 (27.3%) | 32 (16.1%) | 0.002 |
Tumor size (cm, median with IQR) | 3.5 (3.0–4.0) | 3.0 (2.5–4.0) | 3.0 (2.5–4.0) | < 0.0001 |
Operation | 0.337 | |||
 Pancreaticduodenectomy | 65 (64.4%) | 270 (64.6%) | 133 (66.8%) |  |
 Distal pancreatectomy | 30 (29.7%) | 124 (29.7%) | 62 (31.2%) |  |
 Total pancreatectomy | 6 (5.9%) | 24 (5.7%) | 4 (2.0%) |  |
 Perioperative transfusion | 74 (73.2%) | 311 (74.4%) | 160 (80.4%) | 0.212 |
 Operation time (min, median with IQR) | 300 (240–360) | 300 (223.8–345) | 270 (210–330) | 0.055 |
 Bleeding amount (ml, median with IQR) | 300 (200–600) | 300 (200–500) | 400 (200–500) | 0.581 |
 Vascular resection | 21 (20.8%) | 69 (16.5%) | 23 (11.6%) | < 0.0001 |
 R0 resection | 88 (87.1%) | 469 (87.5%) | 79 (97.5%) | 0.027 |
Tumor differentiation | < 0.0001 | |||
 Well-moderate | 23 (22.8%) | 137 (32.8%) | 107 (53.8%) |  |
 Poor | 78 (77.2%) | 281 (67.2%) | 92 (46.2%) |  |
 Margin | 1.4 (0.6–2.0) | 1.0 (0.5–2.0) | 1.0 (0.6–2.5) | 0.687 |
AJCC T-stage | 0.006 | |||
 T1–2 | 66 (65.2%) | 281 (67.2%) | 157 (78.9%) |  |
 T3–4 | 35 (34.7%) | 137 (32.8%) | 42 (21.1%) |  |
AJCC N-stage | 0.006 | |||
 0 | 34 (33.7%) | 184 (44.0%) | 97 (48.7%) |  |
 1 | 50 (49.5%) | 164 (39.2%) | 87 (43.7%) |  |
 2 | 17 (16.8%) | 70 (16.7%) | 15 (7.5%) |  |
 LNM | 67 (66.3%) | 234 (56.0%) | 102 (51.3%) | 0.045 |
 Harvested lymph nodes | 13 (6–21) | 13 (7–19) | 10 (5.5–15.5) | 0.421 |
 Number of LNM | 1 (0–3) | 1 (0–2) | 0 (0–2.0) | 0.019 |
 Positive lymph node ratio | 0.09 (0–0.2) | 0.06 (0–0.19) | 0.04 (0–0.14) | 0.019 |
 Perineural invasion | 91 (90.1%) | 398 (95.2%) | 192 (96.53%) | 0.199 |
AJCC stage | 0.010 | |||
  ≤ 2A | 31 (30.7%) | 254 (60.8%) | 96 (48.2%) |  |
 >2A | 70 (69.3%) | 164 (39.2%) | 103 (51.8%) |  |
Complications | 0.267 | |||
  < 3 | 89 (88.1%) | 351 (84.0%) | 166 (83.4%) |  |
  ≥ 3 | 1 (1.0%) | 15 (3.6%) | 10 (5.0%) |  |
POPF | 0.766 | |||
 Biochemical leak | 52 (51.4%) | 172 (41.4%) | 92 (46.2%) |  |
 Grade B/C POPF | 16 (15.8%) | 57 (13.6%) | 25 (12.6%) |  |
 Adjuvant chemotherapy | 70 (69.3%) | 288 (68.9%) | 141 (70.9%) | 0.160 |
 Gemcitabine | 6 (5.9%) | 37 (8.9%) | 28 (14.1%) |  |
 S-1 or Capecitabine | 5 5.0%) | 26 (6.2%) | 13 (6.5%) |  |
 Combined a | 59 (58.4%) | 225 (53.8%) | 100 (50.2%) |  |
Recurrence site | < 0.0001 | |||
 Local | 10 (9.9%) | 72 (17.2%) | 61 (30.7%) |  |
 Systemic | 67 (66.3%) | 242 (57.9%) | 81 (40.7%) |  |
 Multiple | 13 (12.9%) | 49 (11.7%) | 22 (11.1%) |  |
 Not know | 11 (10.9%) | 55 (13.2%) | 35 (17.6%) |  |
 mDFS | 1.3 (1.1–1.4) | 6.4 (6.0–6.9) | 18.5 (17.3–19.7) | < 0.0001 |
 mOS | 9.8 (7.8–11.7) | 14.7 (13.9–15.8) | 30.8 (29.1–32.5) | < 0.0001 |
 Median total survival | 12.5 (10.7–14.4) | 16.7 (15.7–17.6) | 35.1 (32.1–38.0) | < 0.0001 |